Oral arguments by Illumina and Grail before the US Federal Trade Commission today focused on the competitive impact of the merger on lives saved through Grail’s cancer-detecting blood test, and on the parties’ proposed “open offer” to customers of its gene-sequencing platform.The five commissioners heard arguments in the appeal
* = Required Field
*Areas of Interest
MLex content is primarily organized into different areas of interest that cover the main elements of regulatory risk. Please indicate which ones you would like to be included in your Daily Wrap-up alert
MLex Limited and our LexisNexis Legal & Professional group of companies will use your personal information to administer your account and/or provide the products and services that you have requested from us. We may also contact you in your professional capacity with information about our other products, services and events that we believe may be of interest. You can manage your communication preferences via our Preference Center . You can learn more about how we handle your personal data and your rights by reviewing our Privacy Policy .
Serafina Smith covers mergers and acquisitions for MLex from New York. Before becoming a journalist, Serafina was a paralegal supporting the United States Department of Justice, where she worked on foreign bribery and money laundering cases. She holds a master’s degree in journalism from New York University and a bachelor’s degree in linguistics from Georgetown University.